Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD vs Pirarubicin in Advanced Soft-tissue Sarcoma
NCT03342300Phase 3Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, pirarubicin in soft tissue sarcoma (STS), sponsored by Peking University People's Hospital. Planned start Nov 2017; status: withdrawn.
02
Drugs
doxorubicinpirarubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03342300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342300.